100 related articles for article (PubMed ID: 24518709)
1. Efficacy of neoadjuvant chemotherapy in down staging locally advanced pre-menopausal breast cancer in Eastern Nigeria: is four courses adequate?
Egwuonwu OA; Anyanwu SN; Nwofor AM
J Cancer Res Ther; 2013; 9(4):638-43. PubMed ID: 24518709
[TBL] [Abstract][Full Text] [Related]
2. Default from neoadjuvant chemotherapy in premenopausal female breast cancer patients: what is to blame?
Egwuonwu OA; Anyanwu SN; Nwofor AM
Niger J Clin Pract; 2012; 15(3):265-9. PubMed ID: 22960958
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy for locally advanced premenopausal breast cancer in Nigerian women: early experience.
Anyanwu SN; Nwose P; Ihekwoaba E; Mbaeri AT; Chukwuanukwu TO
Niger J Clin Pract; 2010 Jun; 13(2):215-7. PubMed ID: 20499759
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
[TBL] [Abstract][Full Text] [Related]
6. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
8. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.
Datta NR; Rajkumar A; Basu R
Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108
[TBL] [Abstract][Full Text] [Related]
9. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
10. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
George J; Dharanipragada K; Krishnamachari S; Chandrasekaran A; Sam SS; Sunder E
Clin Breast Cancer; 2009 Aug; 9(3):161-5. PubMed ID: 19661039
[TBL] [Abstract][Full Text] [Related]
11. Breast conservation after induction chemotherapy for locally advanced breast cancer.
Kling KM; Ostrzega N; Schmit P
Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
[TBL] [Abstract][Full Text] [Related]
12. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
13. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
15. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
16. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
17. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J; Oosterkamp HM; Bosch CA; Velds A; Wessels LF; Loo C; Rutgers EJ; Rodenhuis S; van de Vijver MJ
J Clin Oncol; 2005 May; 23(15):3331-42. PubMed ID: 15908647
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
[TBL] [Abstract][Full Text] [Related]
19. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]